Yigal Nochomovitz's questions to Beigene Ltd (ONC) leadership • Q4 2024
Question
Yigal Nochomovitz of Citigroup asked about the BRUKINSA patent settlement extending to 2037 and whether a future fixed-dose oral combination with sonrotoclax could further extend the franchise's patent protection.
Answer
CFO Aaron Rosenberg confirmed the 2037 patent protection for BRUKINSA is a starting point. He emphasized that the broader franchise strategy relies on a combination of assets, including pipeline drugs with patent lives extending well beyond that date, to create a durable and long-lived franchise.